EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review

Victoria E Abadi-Ron, Ana Marenco-Flores, Natalia Rojas-Amaris, Fernando Munguía, Javier Polo-Ibarra, Behnam Saberi, Vilas R Patwardhan, Alan Bonder

Turkish Journal of Gastroenterology · 19.06.2026

DOI: 10.5152/tjg.2026.26267 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Turkish Journal of Gastroenterology, online erschienen am 19.06.2026. Verfasst von Victoria E Abadi-Ron und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Liver Cirrhosis, Biliary. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingLiver Cirrhosis, BiliaryHumansUrsodeoxycholic AcidLiver TransplantationCholagogues and CholereticsDisease ProgressionRisk Assessment

Substanzen

Ursodeoxycholic AcidCholagogues and Choleretics

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
  • Department of Emergency Medicine, Boston Medical Center, Boston University, Boston, USA.

Zitieren

APA

Abadi-Ron, V. E., Marenco-Flores, A., Rojas-Amaris, N., Munguía, F., Polo-Ibarra, J., Saberi, B., Patwardhan, V. R., & Bonder, A. (2026). Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.26267

Vancouver

Abadi-Ron VE, Marenco-Flores A, Rojas-Amaris N, Munguía F, Polo-Ibarra J, Saberi B, et al. Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.26267

BibTeX
@article{AbadiRon2026,
  author = {Abadi-Ron, Victoria E and Marenco-Flores, Ana and Rojas-Amaris, Natalia and Munguía, Fernando and Polo-Ibarra, Javier and Saberi, Behnam and Patwardhan, Vilas R and Bonder, Alan},
  title = {Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review},
  journal = {Turkish Journal of Gastroenterology},
  year = {2026},
  doi = {10.5152/tjg.2026.26267}
}
Kostenlos starten →